<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
<channel>
<title>NARINGENIN ATTENUATES NEUROBEHAVIOURAL DEFICITS AND  BIOCHEMICAL PERTURBATIONS INDUCED BY CHRONIC HYPOXIC  STRESS IN MICE</title>
<link>http://hdl.handle.net/123456789/1740</link>
<description/>
<pubDate>Tue, 17 Mar 2026 15:54:14 GMT</pubDate>
<dc:date>2026-03-17T15:54:14Z</dc:date>
<item>
<title>NARINGENIN ATTENUATES NEUROBEHAVIOURAL DEFICITS AND  BIOCHEMICAL PERTURBATIONS INDUCED BY CHRONIC HYPOXIC  STRESS IN MICE</title>
<link>http://hdl.handle.net/123456789/1741</link>
<description>NARINGENIN ATTENUATES NEUROBEHAVIOURAL DEFICITS AND  BIOCHEMICAL PERTURBATIONS INDUCED BY CHRONIC HYPOXIC  STRESS IN MICE
OLUGBEMIDE, ABIMBOLA SADIAT
Hypoxic stress is known to induce depression, cognitive dysfunction and anxiety-related &#13;
complications through the activation of oxidative and inflammatory signaling pathways. Thus, &#13;
inhibition of these pathways might mitigate hypoxic stress-induced neurobehavioural deficits. &#13;
Experimental studies have shown that naringenin improves neurobehavioural disorders induced &#13;
by ischemic stroke via inhibition of oxidative stress, neuroinflammation and neurodegeneration. &#13;
However, there is paucity of information on its protective effects against neurobehavioural &#13;
deficits induced by Chronic Hypoxic Stress (CHS). Hence, this study was designed to evaluate the &#13;
effects and biochemical mechanisms of naringenin on CHS-induced depression, memory deficit &#13;
and anxiety related behaviours in mice. &#13;
Thirty-five male Swiss-mice (20-22 g) were distributed into 5 groups (n=7) and treated &#13;
intraperitoneally. Mice in groups I (non-stress control) and 2 (stress-control) received 5%-DMSO &#13;
(vehicle), while groups 3-5 were treated with 10, 25 and 50 mg/kg analytical grade of naringenin, &#13;
daily for 14 days. Thirty minutes after daily treatment, each mouse in group 2-5 was subjected to &#13;
15 minutes hypoxic-stress in an air-tight 250 mL cylindrical vessel for 14 consecutive days. The &#13;
neurobehavioural phenotypes (locomotor activity, anxiety, depression and memory) were &#13;
evaluated on day 15 using standard experimental procedures. Thereafter, the animals were &#13;
euthanized and the harvested brains were processed for determination of malondialdehyde, &#13;
reduced glutathione (GSH), nitrite, superoxide-dismutase and catalase using standard biochemical &#13;
techniques. Serum corticosterone and brain Tumor Necrosis Factor-alpha (TNF-α), and &#13;
interleukin-1β were assayed using ELISA kits. The expressions of Inducible Nitric Oxide &#13;
Synthase (iNOS), Nuclear Factor Kappa-B (NF-kB) and Brain Derived Neurotrophic Factor &#13;
(BDNF) were determined using immunohistochemical techniques. The histomorphological &#13;
changes of the amygdala were also determined using hematoxylin and eosin, and cresyl violet &#13;
stains. Data were analysed using descriptive statistics and ANOVA at α0.05. &#13;
Naringenin (25 and 50 mg/kg) relative to stress-control significantly attenuated CHS-induced &#13;
locomotor deficit (11.71±0.57 and 12.29±0.57 vs 8.29±0.68) and prolonged immobility time in &#13;
the test for depression (104.40±9.31 and 139.70±8.34 vs 197.40±6.83sec). It also reduced anxiety like behaviours but did not ameliorate memory deficit induced by CHS. Naringenin (10, 25 and &#13;
50 mg/kg) reduced malondialdehyde concentration (36.23±0.96, 40.65±1.60, 67.39±0.32 vs &#13;
79.86±4.26 μmol/g tissue) and increased GSH levels (20.85±0.63, 21.99±0.74, 21.65±0.46 vs &#13;
17.50±0.50 μmol/g tissue). It also restored the altered brain nitrite content and superoxide &#13;
dismutase activity but not catalase. Naringenin (25 and 50 mg/kg) reduced CHS-induced increase &#13;
in the brain contents of TNF-α (37.43±0.63 and 38.84±2.21 vs 50.14±2.26 pg/mL) and &#13;
interleukin-1β (190.60±11.19, 157.60±6.09 vs 245.70±8.54 pg/mL). The CHS-induced increased &#13;
brain expressions of iNOSand NF-kBimmunopositive cells were attenuated by naringenin. It also &#13;
increased BDNF expressions but did not alter serum corticosterone. Histomorphological &#13;
distortions and loss of neuronal cells in the amygdala induced by CHS was reduced by naringenin. &#13;
Naringenin attenuated depression and anxiety like behaviours induced by chronic hypoxic stress. &#13;
The mechanism was via neuroprotection relating to inhibition of oxidative stress, &#13;
proinflammatory cytokines, expressions of inducible nitric oxide synthase and nuclear factor &#13;
kappa-B, and upregulation of brain derived neurotrophic factor expressions.
</description>
<pubDate>Thu, 01 Jul 2021 00:00:00 GMT</pubDate>
<guid isPermaLink="false">http://hdl.handle.net/123456789/1741</guid>
<dc:date>2021-07-01T00:00:00Z</dc:date>
</item>
</channel>
</rss>
